MAPRE3 and cancer: Investigations into whether EpoD administration causes aberrant MAP phenotypes, such as Benbow and Colleagues (2016) described when treating mice with taxol and describing changes to EB3 expression in vivo, is required to compare our current study with EpoD concentrations used for cancer therapy62.